HELM INTELLIGENCEAMGN
Preparing your analysis.
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Working on your request
We’re bringing the available data and research into view. Your report will appear here when it’s ready.
Investors should consider both the growth potential and the risks associated with Amgen's high valuation and leverage.
Amgen Inc has a market capitalization of $204.49B and a current price of $377.29, reflecting a decrease of 1.32% from the previous close of $382.34. The P/E ratio stands at 26.51, with a P/S ratio of 5.56 and a P/B ratio of 23.62. Year-over-year EPS growth is reported at 88.23%, while revenue growth is at 9.95%. The dividend yield is 2.51%, with a 52-week high of $447.03 and a low of $269.75.
Some investors highlight Amgen's significant EPS growth of 88.23% year-over-year, indicating strong profitability improvements. Additionally, the company has identified 26% growth drivers and potential from its IMDELLTRA and MariTide products, which could enhance future revenue streams.
Conversely, the high P/E ratio of 26.51 may suggest that the stock is priced for perfection, which could deter some value-oriented investors. The debt-to-equity ratio of 5.78 raises concerns about financial leverage and risk, especially in volatile market conditions.
Want AI analysis of your entire portfolio?
Helm Terminal connects to your brokerage, analyzes every holding, and delivers actionable intelligence weekly. Free to start.
Get started freeHelm provides financial data for informational purposes only. This is not financial, investment, or tax advice. Consult a qualified professional before making financial decisions.
Watch my tickers
Get an email when something changes on your tickers: the exact quote, dated and sourced. No account, no brokerage connection, unsubscribe anytime.
Amgen Inc has a market capitalization of $204.49B and a current price of $377.29, reflecting a decrease of 1.32% from the previous close of $382.34. The P/E ratio stands at 26.51, with a P/S ratio of 5.56 and a P/B ratio of 23.62. Year-over-year EPS growth is reported at 88.23%, while revenue growth is at 9.95%. The dividend yield is 2.51%, with a 52-week high of $447.03 and a low of $269.75.
Conversely, the high P/E ratio of 26.51 may suggest that the stock is priced for perfection, which could deter some value-oriented investors. The debt-to-equity ratio of 5.78 raises concerns about financial leverage and risk, especially in volatile market conditions.
Some investors highlight Amgen's significant EPS growth of 88.23% year-over-year, indicating strong profitability improvements. Additionally, the company has identified 26% growth drivers and potential from its IMDELLTRA and MariTide products, which could enhance future revenue streams.
Some investors highlight Amgen's significant EPS growth of 88.23% year-over-year, indicating strong profitability improvements. Additionally, the company has identified 26% growth drivers and potential from its IMDELLTRA and MariTide products, which could enhance future revenue streams. Conversely, the high P/E ratio of 26.51 may suggest that the stock is priced for perfection, which could deter some value-oriented investors. The debt-to-equity ratio of 5.78 raises concerns about financial leverage and risk, especially in volatile market conditions.
Amgen Inc has a market capitalization of $204.49B and a current price of $377.29, reflecting a decrease of 1.32% from the previous close of $382.34. The P/E ratio stands at 26.51, with a P/S ratio of 5.56 and a P/B ratio of 23.62. Year-over-year EPS growth is reported at 88.23%, while revenue growth is at 9.95%. The dividend yield is 2.51%, with a 52-week high of $447.03 and a low of $269.75.
Helm's analysis is generated by an AI model from live market data. It identifies risk signals, opportunities, and key metrics based on current fundamentals, recent price action, and analyst consensus. It does not execute trades, issue certified investment advice, or predict future prices.
Not financial advice. Informational use only. AI-generated content may contain errors. Consult a licensed financial advisor before making investment decisions. Helm Terminal is not registered as an investment advisor.
Helm Terminal offers free AI-powered stock analysis for AMGN at helmterminal.dev/analyze/AMGN, updated continuously during US market hours. No signup required.